Trevi Therapeutics Inc. (TRVI)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
Trevi Therapeutics Q2 Earnings Call Highlights
Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Trevi Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 70 | $835 | $1,277.5 | $442.5 | 52.99% |
| NA Nizar Araji National Bank Of Canada /FI/ | 3,026 | $19,200.65 | $53,862.8 | $34,662.15 | 180.53% |
| BG Bart Gancher Intech Investment Management LLC | 23,102 | $169,205.15 | $411,215.6 | $242,010.45 | 143.03% |
| JM John Malone Amundi | 10,304 | $191,963.52 | $183,411.2 | -$8,552.32 | -4.46% |
 Joseph Castro Nuveen LLC | 765,176 | $12.01M | $13.62M | $1.61M | 13.39% |
Trevi Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CM Connor Murphy BMO Capital | 5,648.72 | $102,693.66 | $104,105.84 | $1,412.18 | 1.38% |
Trevi Therapeutics Inc. (TRVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Trevi Therapeutics Inc. ever had a stock split?
Trevi Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer L. Good CEO | NASDAQ (NMS) Exchange | 89532M101 CUSIP |
| US Country | 34 Employees | - Last Dividend | - Last Split | 7 May 2019 IPO Date |
Overview
Trevi Therapeutics, Inc. is a New Haven, Connecticut-based clinical-stage biopharmaceutical company dedicated to the advancement of innovative treatments for serious neurologically mediated conditions. With a focus on the development and commercialization of their lead product candidate, Haduvio, Trevi Therapeutics is pushing the boundaries of what is possible in the realm of neurologically based treatments. The company was formed in 2011 and has since been on a mission to bring relief to patients suffering from chronic conditions that are currently underserved by the medical community. Through rigorous research and clinical trials, Trevi Therapeutics aims to unlock new potential in the fight against challenging medical conditions, bolstered by a strategic license agreement with Endo Pharmaceuticals Inc.
Products and Services
- Haduvio (Oral Extended-release Nalbuphine) - This is Trevi Therapeutics' leading product candidate, currently undergoing extensive Phase IIb/III clinical trials to assess its efficacy and safety. Below are the primary areas of focus for Haduvio’s application:
- Chronic Pruritus: Pruritus, or intense itching, is a debilitating condition often associated with various underlying diseases. Haduvio is being developed to address this relentless itching, particularly when it becomes chronic and severely impacts the quality of life of patients.
- Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients: IPF is a fatal disease characterized by scarring of the lungs, leading to a progressive decline in lung function. Treatment options are limited, and the symptom of chronic cough significantly reduces patients' quality of life. Haduvio offers hope as a potential treatment to alleviate this distressing symptom.
